Retapamulin

Retapamulin
Klinički podaci
Drugs.com	Monografija
Način primene	topikalno
Identifikatori
CAS broj	224452-66-8
ATC kod	None
PubChem	CID 6918462
DrugBank	DB01256
ChemSpider	5293659
ChEMBL	CHEMBL566434
Hemijski podaci
Formula	C30H47NO4S
Molarna masa	517,763
	SMILES C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CSC1C[C@@H]2CC[C@H](C1)N2C; ;
	InChI InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29+,30+/m1/s1 ; Key:STZYTFJPGGDRJD-FJJJPKKESA-N ;

Retapamulin je organsko jedinjenje, koje sadrži 30 atoma ugljenika i ima molekulsku masu od 517,763 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	6
Broj donora vodonika	1
Broj rotacionih veza	6
Particioni koeficijent^[11] (ALogP)	4,2
Rastvorljivost^[12] (logS, log(mol/L))	-6,5
Polarna površina^[13] (PSA, Å²)	92,1

Reference

^ Jones RN, Fritsche TR, Sader HS, Ross JE: Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. Jones, R. N.; Fritsche, T. R.; Sader, H. S.; Ross, J. E. (2006 Jul). „Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci”. Antimicrobial Agents and Chemotherapy. 50 (7): 2583—6. PMC 1489758 . PMID 16801451. doi:10.1128/AAC.01432-05. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Yang LP, Keam SJ: Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;Yang, L. P.; Keam, S. J. (2008). „Retapamulin: A review of its use in the management of impetigo and other uncomplicated superficial skin infections”. Drugs. 68 (6): 855—73. PMID 18416589. doi:10.2165/00003495-200868060-00008.
^ Novak R, Shlaes DM: The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs. Novak, R.; Shlaes, D. M. (2010 Feb). „The pleuromutilin antibiotics: A new class for human use”. Current Opinion in Investigational Drugs (London, England : 2000). 11 (2): 182—91. PMID 20112168. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Jacobs MR: Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbiol. 2007 Dec;2:591-600. Jacobs, M. R. (2007). „Retapamulin: A semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children”. Future Microbiology. 2 (6): 591—600. PMID 18041900. doi:10.2217/17460913.2.6.591.
^ Parish LC, Parish JL: Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections. Drugs Today (Barc). Parish, L. C.; Parish, J. L. (2008 Feb). „Retapamulin: A new topical antibiotic for the treatment of uncomplicated skin infections”. Drugs of Today (Barcelona, Spain : 1998). 44 (2): 91—102. PMID 18389088. doi:10.1358/dot.2008.44.2.1153446. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Retapamulin for impetigo and other infections. Drug Ther Bull. „Retapamulin for impetigo and other infections”. Drug and Therapeutics Bulletin. 46 (10): 76—9. 2008 Oct. PMID 18832258. doi:10.1136/dtb.2008.09.0023. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Nagabushan H: Retapamulin: a novel topical antibiotic. Indian J Dermatol Venereol Leprol. 2010 Jan-Feb;Nagabushan, H. (2010). „Retapamulin: A novel topical antibiotic”. Indian Journal of Dermatology, Venereology and Leprology. 76 (1): 77—9. PMID 20061745. doi:10.4103/0378-6323.58693 .
^ Shawar R, Scangarella-Oman N, Dalessandro M, Breton J, Twynholm M, Li G, Garges H: Topical retapamulin in the management of infected traumatic skin lesions. Ther Clin Risk Manag. . 5 (1). 2009 Feb: 41—9. PMID 19436611. Проверите вредност парамет(а)ра за датум: |date= (помоћ); Недостаје или је празан параметар |title= (помоћ). Epub 2009 Mar 26.
^ . PMID 21059682. Недостаје или је празан параметар |title= (помоћ)
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Retapamulin

[1] Jones RN, Fritsche TR, Sader HS, Ross JE: Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. Jones, R. N.; Fritsche, T. R.; Sader, H. S.; Ross, J. E. (2006 Jul). „Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci”. Antimicrobial Agents and Chemotherapy. 50 (7): 2583—6. PMC 1489758 . PMID 16801451. doi:10.1128/AAC.01432-05. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[2] Yang LP, Keam SJ: Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;Yang, L. P.; Keam, S. J. (2008). „Retapamulin: A review of its use in the management of impetigo and other uncomplicated superficial skin infections”. Drugs. 68 (6): 855—73. PMID 18416589. doi:10.2165/00003495-200868060-00008.

[3] Novak R, Shlaes DM: The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs. Novak, R.; Shlaes, D. M. (2010 Feb). „The pleuromutilin antibiotics: A new class for human use”. Current Opinion in Investigational Drugs (London, England : 2000). 11 (2): 182—91. PMID 20112168. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[4] Jacobs MR: Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbiol. 2007 Dec;2:591-600. Jacobs, M. R. (2007). „Retapamulin: A semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children”. Future Microbiology. 2 (6): 591—600. PMID 18041900. doi:10.2217/17460913.2.6.591.

[5] Parish LC, Parish JL: Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections. Drugs Today (Barc). Parish, L. C.; Parish, J. L. (2008 Feb). „Retapamulin: A new topical antibiotic for the treatment of uncomplicated skin infections”. Drugs of Today (Barcelona, Spain : 1998). 44 (2): 91—102. PMID 18389088. doi:10.1358/dot.2008.44.2.1153446. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[6] Retapamulin for impetigo and other infections. Drug Ther Bull. „Retapamulin for impetigo and other infections”. Drug and Therapeutics Bulletin. 46 (10): 76—9. 2008 Oct. PMID 18832258. doi:10.1136/dtb.2008.09.0023. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[7] Nagabushan H: Retapamulin: a novel topical antibiotic. Indian J Dermatol Venereol Leprol. 2010 Jan-Feb;Nagabushan, H. (2010). „Retapamulin: A novel topical antibiotic”. Indian Journal of Dermatology, Venereology and Leprology. 76 (1): 77—9. PMID 20061745. doi:10.4103/0378-6323.58693 .

[8] Shawar R, Scangarella-Oman N, Dalessandro M, Breton J, Twynholm M, Li G, Garges H: Topical retapamulin in the management of infected traumatic skin lesions. Ther Clin Risk Manag. . 5 (1). 2009 Feb: 41—9. PMID 19436611. Проверите вредност парамет(а)ра за датум: |date= (помоћ); Недостаје или је празан параметар |title= (помоћ). Epub 2009 Mar 26.

[9] . PMID 21059682. Недостаје или је празан параметар |title= (помоћ)

[10] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[11] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.

[12] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[13] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]